US 11,898,145 B2
Enhanced oligonucleotides for inhibiting RTEL1 expression
Erik Funder, Hørsholm (DK); Natascha Hruschka, Basel (CH); Susanne Kammler, Hørsholm (DK); Erich Koller, Basel (CH); Brian Leonard, Basel (CH); Souphalone Luangsay, Basel (CH); Susanne Mohr, Basel (CH); Tobias Nilsson, Basel (CH); Søren Ottosen, Hørsholm (DK); Lykke Pedersen, Hørsholm (DK); Søren V. Rasmussen, Hørsholm (DK); Steffen Schmidt, Hørsholm (DK); Sabine Sewing, Basel (CH); Daniel Turley, Basel (CH); and Johanna Marie Walther, Basel (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by HOFFMANN-LA ROCHE INC., Little Falls, NJ (US)
Filed on Feb. 1, 2022, as Appl. No. 17/590,754.
Claims priority of application No. 21154701 (EP), filed on Feb. 2, 2021; and application No. 21207002 (EP), filed on Nov. 8, 2021.
Prior Publication US 2022/0251556 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61P 31/20 (2006.01); A61K 31/7088 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 31/7088 (2013.01); A61P 31/20 (2018.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/341 (2013.01); C12N 2310/351 (2013.01)] 17 Claims
OG exemplary drawing
 
1. An antisense oligonucleotide consisting of CTttattataactTgaAtCTC (SEQ ID NO 6), wherein capital letters are beta-D-oxy LNA nucleosides, lowercase letters are DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.